Private equity firm to buy TriZetto for $1.4B

  
U.S. healthcare IT company will be purchased by U.K. equity firm. Source: TriZetto 
Apax Partners, a private equity investment group, has agreed to acquire TriZetto Group, a healthcare IT solutions provider, in a transaction valued at approximately $1.4 billion.

Under the terms of the agreement, the London-based Apax will pay $22 per TriZetto share, a 29 percent premium over the 30-day average closing price of the company's stock.

The board of directors of the Newport News, Calif.-based TriZetto has approved the transaction, which is subject to customary closing conditions, including shareholder and regulatory approvals. TriZetto said the closing is expected to occur in the next four to six months.

BlueCross BlueShield of Tennessee and healthcare company The Regence Group, both of whom are TriZetto customers, are also providing a portion of the funding for the transaction and will be equity investors in the newly private company.

“We see the confluence of healthcare and IT as a key area of focus for strategic investments,” said Buddy Gumina, a partner and head of U.S. healthcare at Apax.

“TriZetto represents a unique asset with a tremendous opportunity to drive positive changes in organized systems of healthcare, both in the United States and abroad.”

 

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.